Novartis RNA Med From $12B Deal Keeps Building Case to Become First Therapy for Rare Muscle DiseaseNews DeskJune 11, 20260 A Novartis RNA therapy reduced blood levels of a protein that’s a biological indicator of a particular form of muscular…
Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise TherapeuticsNews DeskJune 1, 20260 Servier is expanding its scope in neurology to include neuromuscular disorders by acquiring a clinical-stage Edgewise Therapeutics drug that offers…